Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. - Wikidata - wikimedia - TriplyDB

Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia.

Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia.

http://www.wikidata.org/entity/Q34620695

about

An update of current treatments for adult acute myeloid leukemia 'Acute myeloid leukemia: a comprehensive review and 2016 update'Outcomes of haploidentical transplant compared with matched donor allogeneic stem cell transplant.Umbilical Cord Blood Transplantation: Challenges and Future Directions.Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study Emerging therapies for acute myeloid leukemia.Outcomes of UCB transplantation are comparable in FLT3+ AML: results of CIBMTR, EUROCORD and EBMT collaborative analysis.Molecular therapy for acute myeloid leukaemia.The Future of Targeting FLT3 Activation in AML.Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia.Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide.Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults.FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML How I treat FLT3-mutated AML.FLT3 inhibitors: clinical potential in acute myeloid leukemia.FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions.Cord blood transplant for acute myeloid leukaemia.Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma.Life after transplant: are we becoming high maintenance in AML?The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells.Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia.Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT.Acute myeloid leukemia: 2016 Update on risk-stratification and management.Treatment of Acute Myeloid Leukemia with the FLT3 Gene Mutation.Pharmacologic maintenance strategies following allogeneic hematopoietic cell transplantation for acute myeloid leukemia.Inhibition of FLT3 in AML: a focus on sorafenib.Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: a retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO).The role of FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia.Treatment of Relapsed/Refractory Acute Myeloid Leukemia.Preventing relapse after haematopoietic stem cell transplantation for acute leukaemia: the role of post-transplantation minimal residual disease (MRD) monitoring and MRD-directed intervention.Recent advances in hematopoietic stem cell transplantation.Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia.Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis.Reduced-Intensity Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Solid Tumors in Pediatric and Young Adult Patients.Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: An analysis from the acute leukemia working party of the EBMT.Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission.Predictive significance of the European LeukemiaNet classification of genetic aberrations in patients with acute myeloid leukaemia undergoing allogeneic stem cell transplantation.High rate of hematological responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation.Synergistic effect of sorafenib and cGvHD in patients with high-risk FLT3-ITD+AML allows long-term disease control after allogeneic transplantation.

P2860

Q26776396-41853F5E-74A6-4C14-A8D4-A361C3521A9B Q28072539-97FD5667-C464-4B36-BDD0-077FF9B75F66 Q30240140-FA065B95-80DE-4DB6-8A1C-95DF508847DC Q30352323-229F1588-F665-4184-8A0E-A64E6BFDE5D5 Q33424306-7C776138-48F4-4F05-8C74-63FDD8858802 Q33576363-A3C6B71E-9C34-4B2B-9DCB-F96A538ABB45 Q33774504-7F47F0A0-A3BB-4C38-8C4B-1E4370A635BD Q33925672-DFC46D4D-B294-4CE1-A272-D75D9BCE8D46 Q34555386-C2DD50B0-58C8-4532-AC65-D7AEC29793D1 Q35546759-7998C177-AD3C-4208-947F-B87ACED383D2 Q35583434-06748E5C-4429-43ED-AAA4-6396BD414F04 Q36090971-68A1722F-5C4B-4FB1-9BE3-6F5FB8E05C49 Q36484100-2823F222-A81A-4B6B-8D4E-3455C9F98FC9 Q37623389-62749A08-EB99-4674-BD73-9B22B46BAA70 Q37638749-159C7670-087D-46CA-A2D2-EAD42A1A013D Q38675400-EA87CD15-5D1F-4965-88B3-CB54F8C0D63F Q38696346-373DEF34-6F71-4AB1-97F8-20C5BB59D9F2 Q38712298-C83C4792-A75F-4325-8610-B799F7211837 Q38777460-EAB1CB36-A1C4-4FC5-BF82-359F3272BF34 Q38801124-AC66513A-1ED6-4E39-9751-D83E568494FC Q38810393-6A6724B5-3A45-46DB-A215-F68BC6CF93B1 Q38848054-7930E630-596E-4C4F-8DF6-FF24778FC265 Q38863489-E3537FF9-E129-462C-A453-00215E71AD36 Q38897289-EC7CFA26-20BA-401D-AB9D-20F65925BA19 Q38913785-4520DAA3-6D57-421F-80F2-E8765FE6CF9B Q38967853-435EA898-2BB1-4528-81CD-A5ED10127E45 Q38989349-1CB903CB-84A0-4F64-A381-E7F7609DAB61 Q39031946-178B1F53-4D47-456A-9799-85F8679AC2D9 Q39045272-E428A722-88D2-4D35-88FB-DD5F0ED57589 Q39175665-7F50E48D-0525-436D-ABC3-634DD89CDD9C Q39329093-6AC1C0AF-6F6B-4DEC-BF65-B381F36CB1E0 Q39405882-DAC43ED0-8EDD-4D18-98D8-1E5DCF9EE95D Q39474999-D740A9EE-C0AC-4CFB-A5F3-6888F551A91D Q39674948-45EE93C6-D452-4B4A-92EF-BCB0371788E3 Q40093716-297E4552-5819-48D9-AE85-0578EC05149F Q40261211-CAECF56F-A908-4686-ACAC-6DAE1998CFB8 Q40513646-E2550D95-EACB-465D-971F-601831329AB4 Q40525341-57ED61E8-7043-41DD-85D8-AB517D13EE93 Q40639927-A725FBC8-49EA-4B2D-AD7A-EA15BF06CC3D Q40669830-0936F641-07E0-4D0C-A8BC-CD984164F2B6

P2860

Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia.

http://www.wikidata.org/entity/Q34620695

description

2014 nî lūn-bûn

@nan

2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Phase I trial of maintenance s ...... cation acute myeloid leukemia.

@ast

Phase I trial of maintenance s ...... cation acute myeloid leukemia.

@en

Phase I trial of maintenance s ...... cation acute myeloid leukemia.

@nl

type

label

Phase I trial of maintenance s ...... cation acute myeloid leukemia.

@ast

Phase I trial of maintenance s ...... cation acute myeloid leukemia.

@en

Phase I trial of maintenance s ...... cation acute myeloid leukemia.

@nl

prefLabel

Phase I trial of maintenance s ...... cation acute myeloid leukemia.

@ast

Phase I trial of maintenance s ...... cation acute myeloid leukemia.

@en

Phase I trial of maintenance s ...... cation acute myeloid leukemia.

@nl

P1433

Q34620695-18CF5499-FA46-4F16-8D4B-5330C4F0DB00

P1476

Q34620695-41516303-7188-466A-AC59-4060DBE9B009

P2093

Q34620695-109157EF-0434-4091-9125-DC70A21918EA

Q34620695-143A515D-3F8F-4090-A729-94997DCEC344

Q34620695-18E98F70-067A-4501-8640-24A7BF1B563D

Q34620695-24E38973-3695-4926-9A68-086C71464431

Q34620695-25EC55D9-120D-45DC-B3DB-192C345F0DB7

Q34620695-3269C869-F52D-4578-99A8-21E1FEF21ECF

Q34620695-3B742524-7FD0-4D17-B862-A57CFE00B7EE

Q34620695-53DB05ED-B0FF-4DEA-9B33-08471C048E08

Q34620695-737611A3-53C4-4C5D-B368-A73ACF8108C3

Q34620695-83CA11D7-F356-4DCD-9237-3E86F67E5F89

P2860

Q34620695-015AE383-08C6-47DA-A449-32AAA63E74B7

Q34620695-0240BE9D-1A78-4ADE-BAB8-20CE90A48084

Q34620695-17CA9F86-881B-4C53-889A-80A2CDF4C04B

Q34620695-1FE92195-D657-4BCA-AA98-861BFA3BF781

Q34620695-229D4D9B-4B44-4341-AFAA-691B62BD68B1

Q34620695-23B612E2-B9B0-42B3-BCC7-5539BB3E178B

Q34620695-26156DFF-75AC-4E32-A713-D45DFD77FD80

Q34620695-27483BF6-41C1-4007-860B-35E2ABECFE91

Q34620695-29DFDE57-A0D8-403C-8403-5FD940A5B49D

Q34620695-2FBA8D4E-E441-4A72-AF86-EA8D46BD449D

P304

Q34620695-02666C28-A49E-4F39-B362-BBFD0CC4AF50

P31

Q34620695-FCA62D9F-970D-4BBB-8966-D9D221F9B942

P356

Q34620695-88E0C6AF-AD0D-47E1-B2B7-DCD69F7DF8DB

P433

Q34620695-E4C82676-450E-4817-B82D-BE5F7A5635A9

P478

Q34620695-45469C52-EBD8-4049-AE68-B8F89525028D

P50

Q34620695-7405117B-A1E2-4649-AF6B-7E33B5EF57BA

P577

Q34620695-C54B10E9-331F-40EA-A60D-8757CEDE7F8F

P5875

Q34620695-102A2F63-8103-41D8-A23F-EF879AB145E1

P698

Q34620695-85282816-61A0-4451-A2B8-11BBBD9D0AD0

P921

Q34620695-1D728EE2-C079-48FB-82F5-4C2C81D95075

Q34620695-E562CBDA-5B39-45A0-8592-997C675432EA

P932

Q34620695-2E9ED99B-4F8A-4A03-AED8-F5BCFDB94B33

P356

J.BBMT.2014.09.007

P1433

Biology of Blood and Marrow Transplantation

P1476

Phase I trial of maintenance s ...... cation acute myeloid leukemia.

@en

P2093

Amir T Fathi

http://www.w3.org/2001/XMLSchema#string

Amy Joyce

http://www.w3.org/2001/XMLSchema#string

Andrew A Lane

http://www.w3.org/2001/XMLSchema#string

Areej El-Jawahri

http://www.w3.org/2001/XMLSchema#string

Betsy Valles

http://www.w3.org/2001/XMLSchema#string

Bimalangshu R Dey

http://www.w3.org/2001/XMLSchema#string

Candice Del Rio

http://www.w3.org/2001/XMLSchema#string

Christine Connolly

http://www.w3.org/2001/XMLSchema#string

Corey Cutler

http://www.w3.org/2001/XMLSchema#string

Joseph H Antin

http://www.w3.org/2001/XMLSchema#string

P2860

FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo

Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation

FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.

Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib

Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes.

Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.

Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease.

No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials.

P304

2042-2048

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BBMT.2014.09.007

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Sigitas Verselis

P577

2014-09-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

265858976

http://www.w3.org/2001/XMLSchema#string

P698

25239228

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

4253683

http://www.w3.org/2001/XMLSchema#string